COMP <GO>
SUPN vs ABBV // FORWARD P/E MULTIPLE
Supernus Pharmaceuticals Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: SUPN 3
— ABBV 9
▲ FORWARD P/E MULTIPLE LEADER: SUPN
LAST: $41.92 (+0.19%) • MKT CAP: $2.43B
forward-pe
22.0x
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SUPN VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SUPN | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 89.60% | 70.20% | +19.40 | SUPN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -4.50% | 29.00% | -33.50 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.89% | 3.47% | -1.58 | ABBV | /fcf-yield <GO> |
| Operating Margin | -8.70% | 24.60% | -33.30 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -5.40% | 6.90% | -12.30 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 8.60% | 8.60% | 0.00 | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.84 | 5.33 | -0.49 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 7.40% | -0.90 | SUPN | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.0 | 72.8 | -21.79 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 1.15 | -0.27 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 22.0x | 113.1x | -91.10 | SUPN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.43B | $513.86B | -$511.43B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SUPN REV | ABBV REV | SUPN GROSS % | ABBV GROSS % | SUPN FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $719.0M | $61.16B | 89.6% | 70.2% | $46.0M | $17.82B |
| FY 2024 | $661.8M | $56.33B | 88.2% | 70.0% | $171.2M | $17.83B |
| FY 2023 | $607.5M | $54.32B | 44.0% | 44.0% | $83.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SUPN // BETA 0.88
ABBV // BETA 1.15